PharmGKB summary: Caffeine pathway

Pharmacogenetics and Genomics

Volumn 22, Issue 5, 2012, Pages 389-395

  Thorn, Caroline F ^a   Aklillu, Eleni ^b   McDonagh, Ellen M ^a   Klein, Teri E ^a   Altman, Russ B ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2E1; XANTHINE DEHYDROGENASE;

ANXIETY DISORDER; ARTICLE; BIOLOGICAL ACTIVITY; BLADDER CANCER; CANCER RISK; CARDIOVASCULAR RISK; COFFEE; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; ENZYME SUBSTRATE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; HUMAN; INSOMNIA; NEUROPROTECTION; NEUROTRANSMISSION; PARKINSON DISEASE; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SMOKING;

EID: 84859898816     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283505d5e     Document Type: Article

References (42)

1. Mandel HG. Update on caffeine consumption, disposition and action. Food Chem Toxicol 2002; 40:1231-1234. (Pubitemid 35247453)
2. Sawynok J. Methylxanthines and pain. Handb Exp Pharmacol 2011; 200:311-329.
3. Kot M, Daniel WA. Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacol Rep 2008; 60:789-797.
4. Donovan JL, DeVane CL. A primer on caffeine pharmacology and its drug interactions in clinical psychopharmacology. Psychopharmacol Bull 2001; 35:30-48.
5. Prediger RD. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. J Alzheimers Dis 2010; 20 (Suppl 1):S205-S220.
6. Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini EK. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed Chromatogr 2007; 21:190-200.
7. Benowitz NL, Jacob P III, Mayan H, Denaro C. Sympathomimetic effects of paraxanthine and caffeine in humans. Clin Pharmacol Ther 1995; 58:684-691. (Pubitemid 26018853)
8. Kot M, Daniel WA. The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms. Biochem Pharmacol 2008; 76:543-551.
9. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53:503-514. (Pubitemid 23161197)
10. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992; 2:73-77.
11. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004; 76:178-184. (Pubitemid 39013407)
12. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007; 63:537-546. (Pubitemid 46684487)
13. Djordjevic N, Ghotbi R, Jankovic S, Aklillu E. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C >A polymorphism. Eur J Clin Pharmacol 2010; 66:697-703.
14. Cornelis MC, El-Sohemy A, Campos H. Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption. Am J Clin Nutr 2007; 86:240-244. (Pubitemid 47041616)
15. Popat RA, Van Den Eeden SK, Tanner CM, Kamel F, Umbach DM, Marder K, et al. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease. Eur J Neurol 2011; 18:756-765.
16. Facheris MF, Schneider NK, Lesnick TG, de Andrade M, Cunningham JM, Rocca WA, et al. Coffee, caffeine-related genes, and Parkinson's disease: a case-control study. Mov Disord 2008; 23:2033-2040.
17. Tan EK, Chua E, Fook-Chong SM, Teo YY, Yuen Y, Tan L, et al. Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers. Pharmacogenet Genomics 2007; 17:1001-1005. (Pubitemid 350293800)
18. Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006; 295: 1135-1141. (Pubitemid 43352342)
19. Kotsopoulos J, Ghadirian P, El-Sohemy A, Lynch HT, Snyder C, Daly M, et al. The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev 2007; 16:912-916. (Pubitemid 46910091)
20. Kotsopoulos J, Vitonis AF, Terry KL, De Vivo I, Cramer DW, Hankinson SE, et al. Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer. Cancer Causes Control 2009; 20:335-344.
21. Villanueva CM, Silverman DT, Murta-Nascimento C, Malats N, Garcia-Closas M, Castro F, et al. Coffee consumption, genetic susceptibility and bladder cancer risk. Cancer Causes Control 2009; 20:121-127.
22. Sata F, Yamada H, Suzuki K, Saijo Y, Kato EH, Morikawa M, et al. Caffeine intake, CYP1A2 polymorphism and the risk of recurrent pregnancy loss. Mol Hum Reprod 2005; 11:357-360. (Pubitemid 41417869)
23. Schmidt RJ, Romitti PA, Burns TL, Murray JC, Browne ML, Druschel CM, et al. Caffeine, selected metabolic gene variants, and risk for neural tube defects. Birth Defects Res A Clin Mol Teratol 2010; 88:560-569.
24. Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 2003; 64:659-669. (Pubitemid 37048569)
25. Cornelis MC, Monda KL, Yu K, Paynter N, Azzato EM, Bennett SN, et al. Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS Genet 2011; 7:e1002033.
26. Sulem P, Gudbjartsson DF, Geller F, Prokopenko I, Feenstra B, Aben KK, et al. Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. Hum Mol Genet 2011; 20:2071-2077.
27. Alsene K, Deckert J, Sand P, de Wit H. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 2003; 28:1694-1702. (Pubitemid 41070870)
28. Childs E, Hohoff C, Deckert J, Xu K, Badner J, de Wit H. Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 2008; 33:2791-2800.
29. Rogers PJ, Hohoff C, Heatherley SV, Mullings EL, Maxfield PJ, Evershed RP, et al. Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption. Neuropsychopharmacology 2010; 35:1973-1983.
30. Domschke K, Gajewska A,Winter B, Herrmann MJ,Warrings B, Muhlberger A, et al. ADORA2A gene variation, caffeine, and emotional processing: a multi-level interaction on startle reflex. Neuropsychopharmacology 2011; 253 [epub ahead of print].
31. Retey JV, Adam M, Khatami R, Luhmann UF, Jung HH, Berger W, et al. A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clin Pharmacol Ther 2007; 81:692-698. (Pubitemid 46625104)
32. Riksen NP, Franke B, van den Broek P, Smits P, Rongen GA. The 1976C > T polymorphism in the adenosine A2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo. Pharmacogenet Genomics 2007; 17:551-554. (Pubitemid 46905221)
33. Djordjevic N, Carrillo JA, Gervasini G, Jankovic S, Aklillu E. In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. Eur J Clin Pharmacol 2010; 66:571-578.
34. Hamza TH, Chen H, Hill-Burns EM, Rhodes SL, Montimurro J, Kay DM, et al. Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet 2011; 7:e1002237.
35. Arendash GW, Cao C. Caffeine and coffee as therapeutics against Alzheimer's disease. J Alzheimers Dis 2010; 20 (Suppl 1):S117-S126.
36. Miwa S, Sugimoto N, Shirai T, Hayashi K, Nishida H, Ohnari I, et al. Caffeine activates tumor suppressor PTEN in sarcoma cells. Int J Oncol 2011; 39:465-472.
37. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011; 2:135-164.
38. Dominguez-Rojas V, de Juanes-Pardo JR, Astasio-Arbiza P, Ortega-Molina P, Gordillo-Florencio E. Spontaneous abortion in a hospital population: are tobacco and coffee intake risk factors? Eur J Epidemiol 1994; 10: 665-668.
39. Rasch V. Cigarette, alcohol, and caffeine consumption: risk factors for spontaneous abortion. Acta Obstet Gynecol Scand 2003; 82:182-188. (Pubitemid 36349850)
40. Fenster L, Quale C, Hiatt RA,Wilson M,Windham GC, Benowitz NL. Rate of caffeine metabolism and risk of spontaneous abortion. Am J Epidemiol 1998; 147:503-510. (Pubitemid 28146111)
41. Signorello LB, Nordmark A, Granath F, Blot WJ, McLaughlin JK, Anneren G, et al. Caffeine metabolism and the risk of spontaneous abortion of normal karyotype fetuses. Obstet Gynecol 2001; 98:1059-1066. (Pubitemid 34075331)
42. Ingelman-Sundberg M, Sim SC, Nebert DW. Coffee, myocardial infarction, and CYP nomenclature. JAMA 2006; 296:764-765, author reply 765-766. (Pubitemid 44223097)